RIDGEFIELD, Conn. and
INDIANAPOLIS, May 27, 2015 /PRNewswire/ -- The
presentation of 35 abstracts will demonstrate the breadth and depth
of the Boehringer Ingelheim (BIPI) and Eli Lilly and Company (NYSE:
LLY) Diabetes alliance portfolio at the 75th American
Diabetes Association's (ADA) Scientific Sessions® in Boston, June
5-9.
"With growing numbers of people being diagnosed with diabetes,
there is tremendous need for ongoing clinical research to ensure
treatment options and approaches are available to meet patients'
diverse needs," said Thomas Seck, M.D., vice president, Clinical
Development and Medical Affairs - Metabolism at Boehringer
Ingelheim. "As part of our commitment to the diabetes community,
the BI-Lilly Diabetes alliance will present an array of product,
disease state and patient-physician survey data that help address
the needs of adults with diabetes."
Highlighted presentations and posters include:
Empagliflozin/Metformin Data
Sunday, June 7, 2015:
12 p.m. – 2
p.m. EDT – General Poster Session
- Initial Combinations of Empagliflozin and Metformin (EMPA+MET)
in Patients with Type 2 Diabetes (T2DM) (Presenting Author:
Hadjadj, S.) [119-LB]
Empagliflozin plus immediate-release metformin hydrochloride
fixed-dose combination is an investigational compound being studied
for the treatment of adults with T2D. Data on this combination will
be discussed in a late-breaker poster presentation.
IntroDia™ Survey Data
Sunday, June 7, 2015:
12 p.m. – 2
p.m. EDT – General Poster Session
- Physician-Patient Communication At Prescription of an
Additional Oral Agent for Type 2 Diabetes (T2D): Link Between Key
Conversation Elements, Physician Empathy and Patient Outcomes -
Insights From the Global IntroDia™ Study (Presenting Author:
Capehorn, M.) [63-LB]
IntroDia™ is the largest global patient and physician survey
ever conducted that focuses on early conversations about T2D –
providing insights into how physicians and patients interact at
important moments of the diabetes treatment journey. New results
from the survey will be presented as a late-breaker poster
presentation.
Tradjenta® (linagliptin) Data
Sunday, June 7, 2015:
12 p.m. – 2
p.m. EDT - General Poster Session
- Safety and Efficacy of Linagliptin in Patients with Type 2
Diabetes (T2D) and Coronary Artery Disease (CAD): Analysis Of
Pooled Incident Investigator Reported Events From Phase 3 Clinical
Trials (Presenting Author: Leiter, L.) [1246-P]
Linagliptin, marketed as Tradjenta® (linagliptin) 5 mg tablets
in the U.S., is a DPP-4 inhibitor, which works by increasing
hormones that stimulate the pancreas to produce more insulin and
stimulate the liver to produce less glucose. Data will be presented
as a poster presentation.
A complete list of alliance abstracts to be presented or
published at the 75th ADA Scientific Sessions can be
found here.
About Diabetes
Approximately 29 million Americans and an estimated 387 million
people worldwide have type 1 or type 2 diabetes, and nearly 28
percent of Americans with diabetes—totaling 8 million people—are
undiagnosed. In the U.S., approximately 12 percent of those aged 20
and older have diabetes. T2D is the most common type, accounting
for an estimated 90 to 95 percent of all diagnosed adult diabetes
cases in the U.S. Diabetes is a chronic condition that occurs
when the body either does not properly produce, or use, the hormone
insulin.
What is TRADJENTA?
TRADJENTA is a prescription medicine that is used along
with diet and exercise to lower blood sugar in adults with type 2
diabetes.
TRADJENTA is not for people with type 1 diabetes or for people
with diabetic ketoacidosis (increased ketones in the blood or
urine).
If you have had inflammation of the pancreas (pancreatitis) in
the past, it is not known if you have a higher chance of getting
pancreatitis while you take TRADJENTA.
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about
TRADJENTA?
Serious side effects can happen to people taking TRADJENTA,
including inflammation of the pancreas (pancreatitis), which may be
severe and lead to death. Before you start taking TRADJENTA, tell
your doctor if you have ever had pancreatitis, gallstones, a
history of alcoholism, or high triglyceride levels.
Stop taking TRADJENTA and call your doctor right away if you
have pain in your stomach area (abdomen) that is severe and will
not go away. The pain may be felt going from your abdomen through
to your back. The pain may happen with or without vomiting. These
may be symptoms of pancreatitis.
Who should not take TRADJENTA?
Do not take TRADJENTA if you are allergic to linagliptin or any
of the ingredients in TRADJENTA.
Symptoms of a serious allergic reaction to TRADJENTA may include
rash, itching, flaking or peeling; raised red patches on your skin
(hives); swelling of your face, lips, tongue and throat that may
cause difficulty breathing or swallowing. If you have any symptoms
of a serious allergic reaction, stop taking TRADJENTA and call your
doctor or go to the emergency room right away.
What should I tell my doctor before using TRADJENTA?
Tell your doctor about all your medical conditions, including if
you have or have had inflammation of your pancreas
(pancreatitis).
Tell your doctor about all the medicines you take, including
prescription and non-prescription medicines, vitamins, and herbal
supplements. TRADJENTA may affect the way other medicines work, and
other medicines may affect how TRADJENTA works.
Especially tell your doctor if you take
- other medicines that can lower your blood sugar. If you take
TRADJENTA with another medicine that can cause low blood sugar,
such as sulfonylurea or insulin, your risk of getting low blood
sugar is higher. The dose of your sulfonylurea or insulin may need
to be lowered while you take TRADJENTA.
- rifampin (Rifadin®, Rimactane®, Rifater®, Rifamate®), an
antibiotic that is used to treat tuberculosis.
Tell your doctor if you are pregnant or planning to become
pregnant or are breastfeeding or plan to breastfeed.
What are the possible side effects of TRADJENTA?
TRADJENTA may cause serious side effects, including
- Inflammation of the pancreas (pancreatitis).
- Low blood sugar (hypoglycemia), especially if you take
TRADJENTA with another medicine that can cause low blood sugar.
Signs and symptoms of low blood sugar may include headache,
drowsiness, weakness, dizziness, confusion, irritability, hunger,
fast heartbeat, sweating, or feeling jittery.
- Allergic (hypersensitivity) reactions can happen after your
first dose or up to 3 months after starting TRADJENTA. Symptoms may
include swelling of your face, lips, throat, and other areas on
your skin; difficulty with swallowing or breathing; raised, red
areas on your skin (hives); skin rash, itching, flaking, or
peeling.
The most common side effects of TRADJENTA include stuffy or
runny nose, sore throat, cough and diarrhea.
These are not all the possible side effects of TRADJENTA. For
more information, ask your doctor or pharmacist. You are
encouraged to report negative side effects of prescription drugs to
the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
TJ CONS ISI 28MAY2014
Click here for full Prescribing Information, including
Medication Guide.
^The brands listed are trademarks of their respective
owners and are not trademarks of Boehringer Ingelheim
Pharmaceuticals, Inc. The makers of these brands are not affiliated
with and do not endorse Boehringer Ingelheim Pharmaceuticals, Inc.,
or its products.
To learn more about TRADJENTA visit: www.TRADJENTA.com. For full
Prescribing Information and Medication Guide visit:
http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Tradjenta/Tradjenta.pdf.
Please report any unexpected effects or product problems to the
Boehringer Ingelheim Drug Information Unit by calling
1-800-542-6257.
Boehringer Ingelheim and Eli Lilly and Company
In January 2011, Boehringer
Ingelheim and Eli Lilly and Company announced an alliance in
diabetes that centers on compounds representing several of the
largest diabetes treatment classes. This alliance leverages the
strengths of two of the world's leading pharmaceutical companies.
By joining forces, the companies demonstrate commitment in the care
of patients with diabetes and stand together to focus on patient
needs. Find out more about the alliance at
www.boehringer-ingelheim.com or www.lilly.com.
About Boehringer Ingelheim
Boehringer Ingelheim Pharmaceuticals, Inc., based in
Ridgefield, CT, is the largest
U.S. subsidiary of Boehringer Ingelheim Corporation.
Boehringer Ingelheim is one of the world's 20 leading
pharmaceutical companies. Headquartered in Ingelheim, Germany, the company operates globally with
146 affiliates and more than 47,000 employees. Since its
founding in 1885, the family-owned company has been committed to
researching, developing, manufacturing and marketing novel
treatments for human and veterinary medicine.
Boehringer Ingelheim is committed to improving lives and
providing valuable services and support to patients and families.
Our employees create and engage in programs that strengthen our
communities. To learn more about how we make more health for more
people, visit our Corporate Social Responsibility Report.
In 2014, Boehringer Ingelheim achieved net sales of about
$16.96 billion dollars
(13.3 billion euros). R&D expenditure corresponds to
19.9 percent of its net sales.
For more information please visit
www.us.boehringer-ingelheim.com, or follow us on Twitter
@BoehringerUS.
About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when
we introduced the world's first commercial insulin. Today we are
building upon this heritage by working to meet the diverse needs of
people with diabetes and those who care for them. Through research
and collaboration, a broad and growing product portfolio and a
continued determination to provide real solutions—from medicines to
support programs and more—we strive to make life better for all
those affected by diabetes around the world. For more information,
visit www.lillydiabetes.com.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with
discovery to make life better for people around the world. We were
founded more than a century ago by a man committed to creating
high-quality medicines that meet real needs, and today we remain
true to that mission in all our work. Across the globe, Lilly
employees work to discover and bring life-changing medicines to
those who need them, improve the understanding and management of
disease, and give back to communities through philanthropy and
volunteerism. To learn more about Lilly, please visit us at
www.lilly.com and newsroom.lilly.com/social-channels.
This press release contains forward looking statements about
TRADJENTA and the investigational fixed-dose combination of
empagliflozin and metformin for the treatment of type 2 diabetes
along with diet and exercise. It reflects Lilly's current beliefs;
however, as with any such undertaking, there are substantial risks
and uncertainties in the process of drug development and
commercialization. There is no guarantee that future study results
and patient experience will be consistent with study findings to
date, that the investigational fixed-dose combination of
empagliflozin and metformin will be approved or be commercially
successful, or that TRADJENTA will receive additional regulatory
approvals. For further discussion of these and other risks and
uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed
with the U.S. Securities and Exchange Commission. Except as
required by law, Lilly undertakes no duty to update forward-looking
statements.
P-LLY
PR-TJ-0003
CONTACT:
Emily Baier
Geary, Public Relations
Boehringer Ingelheim Pharmaceuticals, Inc.
Email: emily.geary@boehringer-ingelheim.com
Phone: (203) 791-5997
Molly McCully
Communications Manager
Lilly Diabetes
Email: mccully_molly@lilly.com
Phone: (317) 478-5423
Logo - http://photos.prnewswire.com/prnh/20031219/LLYLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/boehringer-ingelheim-and-lilly-diabetes-alliance-to-present-data-from-35-studies-at-the-american-diabetes-associations-75th-scientific-sessions-300089045.html
SOURCE Eli Lilly and Company; Boehringer Ingelheim
Pharmaceuticals, Inc.